[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608725":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":36,"responsibleParty":63,"collaborators":20,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":20,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":20,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"GPN Vaccines","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Gamma -PN","EXPERIMENTAL","Intramuscular administration 500 mcg",[13],"Biological: Gamma-PN",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Gamma-PN","Killed whole-cell pneumococcal vaccine",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Eve Kennedy, PhD","GPN Vaccines Ltd","STUDY_DIRECTOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Nerissa Lakhan, PhD","CONTACT","+61-432 161 783","nerissa@gpnvaccines.com",{"name":33,"role":29,"phone":34,"phoneExt":20,"email":35},"Paul E Rolan, MD","+61-405 670 420","paul@gpnvaccines.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"University of Adelaide Clinical Research Facility","RECRUITING","Adelaide","South Australia","5000","Australia","AU",{"type":46,"coordinates":47},"Point",[48,49],138.59863,-34.92866,{"lat":49,"lon":48},[52,56,60],{"name":53,"role":29,"phone":54,"phoneExt":20,"email":55},"Kirstee Smith","+61-481-589 855","kirstee.smith@adelaide.edu.au",{"name":57,"role":29,"phone":20,"phoneExt":58,"email":59},"Sepehr Shakib, MD PhD","+61-411-100 27","sepehr.shakib@adelaide.edu.au",{"name":61,"role":62,"phone":20,"phoneExt":20,"email":20},"Tom Polasek, MD PhD","PRINCIPAL_INVESTIGATOR",{"type":64,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100608725","phase-1-serum-collection-study-for-assay-development-100608725",false,"NCT07205289","Serum Collection Study for Assay Development","A Phase 1B Open-label Study to Collect Serum Following Vaccination With Killed Whole-cell Pneumococcal Vaccine (Gamma-PN) in Adults for Use in Assay Validation","Inclusion Criteria:\n\n* good general health\n\nExclusion Criteria:\n\n* no previous pneumococcal vaccine",true,"ALL","18 Years","69 Years",{"count":77,"type":78},12,"ESTIMATED","INTERVENTIONAL",[81],"PHASE1","The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation",[84,85],"Pneumococcal Disease, Invasive","Pneumococcal Disease",[87],"Vaccination pneumococcal","2025-09-25",{"date":90,"type":91},"2025-10-03","ACTUAL",{"date":93,"type":78},"2025-10",{"date":95,"type":78},"2026-06",{"name":5,"class":6},1]